Pages Menu
FacebookTwitterPinterestRss
Categories Menu

Posted by on Mar 29, 2018 in Foundation NewsLine, Type C |

CTD Holdings Press Release

PRESS RELEASE FROM CTD HOLDINGS

CTD Holdings Conducts Initial Review of Safety Data for its Phase I and Phase I/II Trials of Trappsol® Cyclo™ to Treat Niemann-Pick Disease Type C.

CLICK HERE for the complete announcement.